Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Dallas Pediatric Neurology Associates
mi
from
Dallas, TX
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Dallas Pediatric Neurology Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Neurological Clinic - Texas
mi
from
Dallas, TX
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Neurological Clinic - Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Texas Tech University Health Sciences Center
mi
from
El Paso, TX
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Texas Tech University Health Sciences Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Clinical Research Facility
mi
from
Houston, TX
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Clinical Research Facility
mi
from
Richmond, VA
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Clinical Research Facility
mi
from
Seattle, WA
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated:  10/30/2015
mi
from
Capital Federal- Provincia de Buenos Aires.,
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Status: Enrolling
Updated: 10/30/2015
mi
from
Capital Federal- Provincia de Buenos Aires.,
Click here to add this to my saved trials
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/2/2015
Dept. of Neuro Surgery
mi
from
Little Rock, AR
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/2/2015
Dept. of Neuro Surgery
mi
from
Little Rock, AR
Click here to add this to my saved trials
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/2/2015
USF Physicians Group
mi
from
Tampa, FL
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/2/2015
USF Physicians Group
mi
from
Tampa, FL
Click here to add this to my saved trials
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/2/2015
Clinical Trials
mi
from
Detroit, MI
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/2/2015
Clinical Trials
mi
from
Detroit, MI
Click here to add this to my saved trials
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/2/2015
Medical College of Ohio Comprehensive Epilepsy Ctr.
mi
from
Toledo, OH
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/2/2015
Medical College of Ohio Comprehensive Epilepsy Ctr.
mi
from
Toledo, OH
Click here to add this to my saved trials
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated:  11/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Status: Enrolling
Updated: 11/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
mi
from
Toms River, NJ
Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
Inflammation and Post-Stroke Depression
Inflammation and Post-Stroke Depression
Status: Enrolling
Updated:  11/2/2015
Rutgers, The State University
mi
from
New Brunswick, NJ
Inflammation and Post-Stroke Depression
Inflammation and Post-Stroke Depression
Status: Enrolling
Updated: 11/2/2015
Rutgers, The State University
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated:  11/3/2015
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated: 11/3/2015
Southwest Autism Research and Resource Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated:  11/3/2015
Arkansas Children's Hospital Research Institute
mi
from
Little Rock, AR
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated: 11/3/2015
Arkansas Children's Hospital Research Institute
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated:  11/3/2015
Baber Research Group
mi
from
Naperville, IL
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated: 11/3/2015
Baber Research Group
mi
from
Naperville, IL
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated:  11/3/2015
Montefiore Medical Center Dept. of Psychiatry, Child Annex
mi
from
Bronx, NY
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated: 11/3/2015
Montefiore Medical Center Dept. of Psychiatry, Child Annex
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated:  11/3/2015
Red Oak Psychiatry
mi
from
Houston, TX
Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status: Enrolling
Updated: 11/3/2015
Red Oak Psychiatry
mi
from
Houston, TX
Click here to add this to my saved trials
How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units
Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists
Status: Enrolling
Updated:  11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units
Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists
Status: Enrolling
Updated: 11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
Status: Enrolling
Updated:  11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
Status: Enrolling
Updated: 11/4/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Strength, Flexibility, And Balance Therapy After Stroke
Yoga as a Complex Intervention for Vets With Stroke
Status: Enrolling
Updated:  11/4/2015
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Strength, Flexibility, And Balance Therapy After Stroke
Yoga as a Complex Intervention for Vets With Stroke
Status: Enrolling
Updated: 11/4/2015
Richard L. Roudebush VA Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Mechanisms of Neuromuscular Fatigue Post Stroke
Mechanisms of Neuromuscular Fatigue Post Stroke
Status: Enrolling
Updated:  11/4/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Mechanisms of Neuromuscular Fatigue Post Stroke
Mechanisms of Neuromuscular Fatigue Post Stroke
Status: Enrolling
Updated: 11/4/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Little Rock, AR
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Anaheim, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Glendale, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Irvine, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Long Beach, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
National City, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Norwalk, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Norwalk, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Oakland, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Oakland, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Oceanside, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
San Bernandino, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
San Bernandino, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
San Diego, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Torrance, CA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Bradenton, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Hialeah, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Kissimmee, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Leesburg, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Leesburg, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Maitland, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Maitland, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Miami, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
North Miami, FL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Chicago, IL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Oak Brook, IL
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Oak Brook, IL
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Shreveport, LA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Glen Burnie, MD
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated:  11/4/2015
Clinical Research Facility
mi
from
Worcester, MA
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia
Status: Enrolling
Updated: 11/4/2015
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials